The shortage of essential chemotherapy drugs in the United States.
about
The continuing impact of oncology drug shortagesOncology drug shortages in americaChemotherapy drug shortages in pediatric oncology: a consensus statementInsights into European drug shortages: a survey of hospital pharmacistsAccess to Cancer Care and General Medical Care Services Among Cancer Survivors in the United States: An Analysis of 2011 Medical Expenditure Panel Survey Data.Medicines shortages-unpicking the evidence from a year in South AfricaFormulary Selection Criteria for Biosimilars: Considerations for US Health-System PharmacistsOncologists' experiences with drug shortagesAn open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.Oncology and the Internet: regulatory failure and reform.The high cost of cancer drugs and what we can do about it.Ethical issues for control-arm patients after revelation of benefits of experimental therapy: a framework modeled in neuroblastomaCancer survivors in the United States: prevalence across the survivorship trajectory and implications for care.Impact of oncology drug shortages on patient therapy: unplanned treatment changesAddressing cost-related barriers to prescription drug use in Canada.US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins.Managing unexpected events in the manufacturing of biologic medicines.Clinical dilemmas and a review of strategies to manage drug shortages.Critical drug shortages: implications for emergency medicine.Scientific, economic, regulatory, and ethical challenges of bringing science-based pediatric nutrition products to the U.S. market and ensuring their availability for patients.After counterfeit Avastin®--what have we learned and what can be done?Medicine shortages in Australia: causes, impact and management strategies in the community setting.The Impact of Shortages on Medication Prices: Implications for Shortage Prevention.Drug shortages: Implications for medical toxicology.The BCG Shortage.The adverse effects of brand-name drug prescribing.Shortages of medicines: a complex global challenge.Process evaluation of knowledge transfer across industries: Leveraging Coca-Cola's supply chain expertise for medicine availability in Tanzania.A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia.Drug shortages in Canadian anesthesia: a national survey.Is antihistaminergic H2 really useful in prevention of hypersensitivity induced by paclitaxel?Preventing shortages of biologic medicines.Antimicrobial Drug Shortages: A Crisis Amidst the Epidemic and the Need for Antimicrobial Stewardship Efforts to Lessen the EffectsA challenge for healthcare but just another opportunity for illegitimate online sellers: Dubious market of shortage oncology drugs
P2860
Q27022902-097833EE-4FE8-426A-A613-B4E16BC0EE76Q27024167-70ABBF56-03C8-4B4E-BDEC-98FB95CA518CQ28307153-C9443894-2CDE-4165-B8E3-A0637FFFC377Q28544114-A3A031B9-B810-49C6-A188-E506368CC626Q31156878-1B97A4C2-794E-4ADE-BA76-C96BD7FF0E56Q33732967-F53FFDFE-464B-4870-8A97-EBFF5F5A3628Q34612781-CE550139-B41F-4EAB-9DAB-00A3B19A66E0Q35210620-FFE06484-4D0D-4871-B5D5-3DDE69B3F9F4Q35868171-5B7F9817-9DF1-4DC7-8FAC-ED98CE6B3061Q36406068-20F9CB62-1959-4123-8181-109D3AFEC56AQ36512856-EA22BD5A-53CE-4B0F-B1D6-AFEEAB23B1E0Q36589638-ACF3B2AC-DE80-4BAD-BF61-589375E802E5Q36846576-48E1A584-CE45-45D8-B86E-DA0686FA9766Q37008542-5337065A-21D6-47BB-A3C6-6497C8B08A78Q37614006-8EC2E1C3-A3DE-4F02-92BB-12B42A9E3898Q37974873-62F62550-821B-4150-9E70-CE3BD5D8C94BQ38093121-D48CCCD5-01C9-40D9-9C83-C1719290712CQ38095836-863F4BF9-E4A6-4E2D-A70E-FA806C757735Q38231341-FFD5207A-09B7-43C8-8C1B-8C96C018930EQ38253579-FE06AE5C-B157-4CC0-8BCD-7986B6461090Q38367161-35873B3F-E88D-4FAA-8C5E-D064E8C76A95Q38844824-541D9A64-A4F7-4ADD-BA5A-45A9712B13A8Q39259740-04FB14CD-5057-4CEB-BD7A-C42DD6E7BD0EQ40964486-0FA28746-F675-4F06-BFB1-5DE4A0C676C2Q41273526-C9F0706F-37CB-462A-812D-9CFB9A9FE8ABQ41949395-1DBD30FF-78FA-4B41-B3AF-EA028C7F8A13Q42563777-F44AD53B-60F9-41F2-953A-D77556B8B206Q43924022-AB6FF46F-6D6F-424A-8476-4DD396652BA5Q45785797-B5574E34-9B75-4EBD-8C61-BE87DE549B89Q45901925-10215BE6-280C-4BB4-8496-9DAAEB39ECBAQ48133146-AEF12624-BA30-4241-9CFB-CC608F99A127Q52646548-AEEE5F4E-8FED-4A2E-BA50-24C30570B715Q57779691-9B50C41A-6418-4A45-B29D-ABEEB3EF89B7Q58699813-2769BBA7-632B-4BC1-A731-3C4F429AF611
P2860
The shortage of essential chemotherapy drugs in the United States.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
The shortage of essential chemotherapy drugs in the United States.
@en
The shortage of essential chemotherapy drugs in the United States.
@nl
type
label
The shortage of essential chemotherapy drugs in the United States.
@en
The shortage of essential chemotherapy drugs in the United States.
@nl
prefLabel
The shortage of essential chemotherapy drugs in the United States.
@en
The shortage of essential chemotherapy drugs in the United States.
@nl
P921
P356
P1476
The shortage of essential chemotherapy drugs in the United States
@en
P2093
Mandy L Gatesman
P304
P356
10.1056/NEJMP1109772
P407
P577
2011-10-31T00:00:00Z